A Comparative Efficacy and Safety Study Between Two Silver Containing Dressings In Post-Op Wound Healing

Surgical Wound Clinical Trial

Official title:

A Comparative Efficacy and Safety Study Between BCT Silver Bandage and Aquacel® Ag. Dressing In Obstetrical and Gynecological Post-Op Wound Healing

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01605968
• Other study ID #: CS11176
• Status: Terminated
• Phase: N/A
• First received: May 23, 2012
• Last updated: July 12, 2017
• Start date: June 2012
• Est. completion date: January 2014

Study information

• Verified date: July 2017
• Source: Bio-medical Carbon Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Study objective:

The objective of this study is to evaluate through clinical criteria the clinical efficacy and safety of BCT Silver Bandage role in obstetrical and gynecological wound healing is as effective and safe as Aquacel® Ag. Dressing.

Study devices:

• Study device: BCT Silver Bandage

• Comparator device:"ConvaTec"Aquacel® Ag Hydrofiber Dressing

Study design:

• Randomized, Open-label, interventional, comparative, preventive study with Blinded evaluator.

• All subjects must meet all the inclusion & exclusion criteria to enter this study in pre-operative phase.

• Eligible subjects will be enrolled after a scheduled operative procedure.

• There is SEVEN visits in this study (one screening eligibility phase up to 7 days before OP day, and four post-op treatment scheduled visits consisting on 1st , 3rd day, 5th day, 12th day and two follow up visit on the 28th and the 42nd post-operative day.

• During each scheduled visit, each subject will have colored picture of his wound after dressing been removed, and on visit V6 for wound evaluation by blinded PI.

Number of subjects: It is expected to recruit ≧150 eligible subjects.

Study Duration: About eighteen month.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 38
• Est. completion date: January 2014
• Est. primary completion date: October 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Male/Female of any race aged between 18 - 70 years old

• The subject is willing and able to understand, sign and date the study Informed Consent, and be able to adhere to the scheduled visits regimen.

• The subject is having surgery (Cesarean pfannenstiel or Open Laparotomy incision) within 1 week

Exclusion Criteria:

• Patients with known allergy or topical hypersensitivity to ionic silver or alginate

• Any systemic or local active dermatological disease that might interfere with the evaluation of the surgical site such as eczema, psoriasis, skin cancer, scleroderma, chronic urticarial

• Patients undergoing MRI (Magnetic Resonance Imaging) examination.

• Subject residence is outside the study center city

• Patients was participating in another clinical trial less than 30 days before participation in this trial

Related Conditions & MeSH terms

• Surgical Wound
• Wounds and Injuries

Intervention

Device:
• BCT Silver Bandage
Activated carbon fiber impregnated with silver particles
• Aquacel® Ag. Dressing
Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.

Locations

Country	Name	City	State
Taiwan	Dep. of Gynecology and Obstetrics, Chung-Shan Medical University Hospital	Taichung City

Sponsors (2)

Lead Sponsor	Collaborator
Bio-medical Carbon Technology Co., Ltd.	Chung Shan Medical University

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy measurements	Wound infection rate within 5 days after operation; Wound healing evaluation by Stony Brook Scar Evaluation Scale (SBSES), to be evaluated by blinded PI at V6; Skin discoloration around the incision wound and/or wound keloid formation rate at V6; Patient and Observer Scar Assessment Scale (POSAS) on V3, V5 and V6	42 days after operation
Secondary	Safety Measurement	The incidence of postoperative skin reactions (defined as blisters, itching, erythematous change around the surgical wound site) within 5 days after operation	42 days after operation